Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells

被引:34
作者
Karimzadeh, Mahmonir [1 ]
Rashidi, Ladan [2 ]
Ganji, Fariba [3 ]
机构
[1] Payam Noor Univ, Dept Chem Engn, Tehran, Iran
[2] Iranian Natl Stand Org, Stand Res Inst, Fac Food Ind & Agr, POB 31585-163, Karaj, Iran
[3] Tarbiat Modares Univ, Biotechnol Div, Fac Chem Engn, POB 14115-143, Tehran, Iran
关键词
Rivastigmine hydrogen tartrate; cytotoxicity; nanoparticles; Alzheimer; mesoporous silica; DRUG-DELIVERY; CHITOSAN; SYSTEM;
D O I
10.1080/03639045.2016.1275668
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Rivastigmine hydrogen tartrate (RT) is a molecule with both hydrophilic and hydrophobic properties used for the treatment of the Alzheimer's disease. In this work, the larger pore size of mesoporous silica nanoparticles (P1-MSN) was synthesized and then, P1-MSN were functionalized by succinic anhydride (S-P1MSN) and 3-aminopropyltriethoxysilane (APTES) (AP-CO-P1-MSN) using the grafting and co-condensation methods, respectively. A new method was used for the functionalization of P1-MSN by succinic anhydride at room temperature. Nanoparticles were characterized by special instrumental analysis and loaded by RT. Maximum entrapment efficiency and RT loading percentage into P1-MSN, AP-CO-P1-MSN and S-P1-MSN were respectively obtained as 21.26 and 25.5%, 41.5 and 49.8%, and 11.9 and 14.28% for 24 h. In the simulated gastric and body fluids, the release rate of RT-loaded AP-CO-P1-MSN (AP-CO-P1-MSN-RT) was lower than that of other RT-loaded nanoparticles. In oral pathway, the sustained release of RT was observed in AP-CO-P1-MSN-RT. Moreover, no cytotoxicity effect was observed for P1-MSN, but the cells treated by APCO- P1-MSN showed a reduction in SY5Y cell viability due to easy entrance of these nanoparticles and their accumulation in different parts of the cell as observed by TEM.
引用
收藏
页码:628 / 636
页数:9
相关论文
共 24 条
[1]   The burden of dementia - A medical and research perspective [J].
Antuono, P ;
Beyer, J .
THEORETICAL MEDICINE AND BIOETHICS, 1999, 20 (01) :3-13
[2]   Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles [J].
Avachat, Amelia M. ;
Oswal, Yogesh M. ;
Gujar, Kishor N. ;
Shah, Rohit D. .
CURRENT DRUG DELIVERY, 2014, 11 (03) :359-370
[3]   A STRATEGY FOR DELIVERING PEPTIDES INTO THE CENTRAL-NERVOUS-SYSTEM BY SEQUENTIAL METABOLISM [J].
BODOR, N ;
PROKAI, L ;
WU, WM ;
FARAG, H ;
JONALAGADDA, S ;
KAWAMURA, M ;
SIMPKINS, J .
SCIENCE, 1992, 257 (5077) :1698-1700
[4]   The role of systemic cytotoxic therapy for prostate cancer [J].
Chang, Sam S. ;
Kibel, Adam S. .
BJU INTERNATIONAL, 2009, 103 (01) :8-17
[5]   Mechanised nanoparticles for drug delivery [J].
Coti, Karla K. ;
Belowich, Matthew E. ;
Liong, Monty ;
Ambrogio, Michael W. ;
Lau, Yuen A. ;
Khatib, Hussam A. ;
Zink, Jeffrey I. ;
Khashab, Niveen M. ;
Stoddart, J. Fraser .
NANOSCALE, 2009, 1 (01) :16-39
[6]   A Nanoparticulate drug-delivery system for rivastigmine:: Physico-chemical and in vitro biological characterization [J].
Craparo, Ernanuela Fabiola ;
Pitarresi, Giovanna ;
Bondi, Maria Luisa ;
Casaletto, Maria Pia ;
Licciardi, Mariano ;
Giarnmona, Gaetano .
MACROMOLECULAR BIOSCIENCE, 2008, 8 (03) :247-259
[7]   Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting [J].
Fazil, Mohammad ;
Md, Shadab ;
Hague, Shadabul ;
Kumar, Manish ;
Baboota, Sanjula ;
Sahni, Jasjeet Kaur ;
Ali, Javed .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 47 (01) :6-15
[8]   Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies [J].
Joshi, Shrinidh A. ;
Chavhan, Sandip S. ;
Sawant, Krutika K. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2010, 76 (02) :189-199
[9]  
Lanctôt KL, 2003, CAN MED ASSOC J, V169, P557
[10]   Use of the ninhydrin assay to measure the release of chitosan from oral solid dosage forms [J].
Leane, MM ;
Nankervis, R ;
Smith, A ;
Illum, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 271 (1-2) :241-249